LILLY'S TERIPARATIDE GETS POSITIVE OPINION FROM EUROPEAN CPMP.Lilly (NYSE NYSE See: New York Stock Exchange :LLY) has announced that the European Committee for Proprietary Medicinal Products (CPMP CPMP Committee for Proprietary Medicinal Products CPMP Core-Plus Mathematics Project CPMP Crew Procedures Management Plan (NASA) CPMP Canadian Project Management Professional CPMP Corporate Planning and Management Practices ) has issued a positive opinion for teriparatide (rDNA origin) injection (proposed European brand name FORSTEO(R)), a bone formation agent for the treatment of established osteoporosis in postmenopausal post·men·o·paus·al adj. Of or occurring in the time following menopause. postmenopausal Change of life Gynecology adjective Referring to the time in ♀ when menstrual periods stop for ≥ 1 yr women who are at high risk of a fracture. The CPMP has recommended to the European Commission European Commission, branch of the governing body of the European Union (EU) invested with executive and some legislative powers. Located in Brussels, Belgium, it was founded in 1967 when the three treaty organizations comprising what was then the European Community that approval for teriparatide should be granted. Teriparatide, which will be known in the rest of the world as FORTEO(R), has already received U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) approval. "We are extremely pleased by the CPMP's recommendation for approval of teriparatide in Europe," said John C. Lechleiter, Ph.D., Lilly executive vice president, pharmaceutical products and corporate development. "The adoption of a positive opinion for teriparatide by the CPMP underscores the strength of the scientific data supporting the use of this unique and innovative product to treat a devastating dev·as·tate tr.v. dev·as·tat·ed, dev·as·tat·ing, dev·as·tates 1. To lay waste; destroy. 2. To overwhelm; confound; stun: was devastated by the rude remark. disease." The CPMP, comprised of regulators from the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community countries, based its positive opinion on its review of the comprehensive data package for teriparatide. More than 2,800 women and men were randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. in studies to characterize the safety and efficacy of teriparatide. Following the CPMP's positive opinion, the application will be reviewed by the European Commission (EC), which has authority to grant marketing authorization for the European Union. Lilly anticipates a decision from the EC in Spring 2003. "There is a great need for new treatment options for severe osteoporosis. Every 30 seconds someone in Europe has a fracture as a result of osteoporosis," said Richard Pilnik, president of European operations for Lilly. "If approved by the European Commission, teriparatide would be the first bone formation agent available for marketing in all of the EU, providing a new treatment approach for those with established osteoporosis who are at high risk of osteoporosis-related fracture." A Critical Need Osteoporosis is a global problem, affecting more than 150 million people worldwide. One in three postmenopausal women will be affected by osteoporosis(1), and as the population of the world both grows and ages it is becoming an increasingly significant cause of mortality and morbidity(2). Studies suggest that osteoporosis may be a quickly progressing disease once a fracture occurs. The accumulation of multiple spinal fractures may result in pain, height loss, deformity Deformity See also Lameness. Calmady, Sir Richard born without lower legs. [Br. Lit.: Sir Richard Calmady, Walsh Modern, 84] Carey, Philip embittered young man with club foot seeks fulfillment. [Br. Lit. , functional limitations and diminished quality of life(3). The condition costs national treasuries in the EU more than EURO 4.8 billion annually in hospital healthcare alone. About Lilly Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information -- for some of the world's most urgent medical needs. For more information, call 317/985-4045. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion